Kura Oncology (KURA)

$KURA the worst stock to own

Attached are all comm'l-stage oncology focused bios down 7%+ from closing highs over the last 5 days. $SNDX has 2 FDA approved drugs. One is 50/50 partner with INCY on Niktimvo. Kadmon Holdings may be a good peer for Niktimvo acquired for $1.9B. A financier paid $350MM for a 14% share suggesting a $2.5B valuation (again SDNX is 50/50). Ziftomenib from $KURA is a good peer for Revumenib (but has better SE profile). KURA trades for less than cash in the bank. $AUTL is again trading for cash. Look at $IMCR over 12 months & you'll understand their drop. With multiple late data reads in the next 18 months, it would appear M&A is unlikely but of course we could be wrong. $DAWN announced last week they hired a VP of R&D so it would also appear M&A is out to save shareholders. Ojemda's patent expires in 6/2035. Will Ojemda be more valuable in 2 years (there's enough patient data to know if Firefly will succeed). This is for entertainment only. This is not investment advice.

$KURA $5S on deck? Looking that way

$KURA Ratings are all rising.

Changes in share price for all comm'l-stage oncology focused bios for the 5-day week ending Friday June 13, 2025. After a couple of good weeks, after an abysmal performance since 11/2024, most bios in this peer group were down while the XBI was only down 1%. $NUVB got its 1st approval Wednesday which was 12 days before PDUFA. $AUTL is well off its lows in the $1.20s/sh just a few weeks ago peaking in the $2.30s before falling back. AUTL has 260MM share o/s so a $1 move is a meaningful change in valuation. $SNDX had also been doing well. With 2 FDA approved therapies, once would think the risk/reward profile insures material changes week to week. Ziftomenib from $KURA is a SNDX Revumenib peer but supposedly comes with 1 less meaningful side effect. KURA trades for well below cash $VSTM got 2nd approval 5 weeks ago a full seven weeks before PDUFA. VSTM closed 5/8/25 @ roughly $7/share & closed today at $5.60. As always, this is not investment advice.

$KURA this place sucks

$KURA My bet, Kyowa is working to BO Kura and they are working with the hedge funds to achieve this. hedge funds win in the long run, Kyowa wins in the long run. Only those who accumulate here will win with them.

$KURA Very interesting move in KURA. There was definitely manipulation today. Institutions are divided as are the hedge funds. With the cash pile on hand and increasingly positive results, KURA can easily become a darling again. Remember, the major drop was on their deal with Kyowa: "Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. –"

$KURA this thing is never positive

$KURA Added 4K shares. We goin up

$KURA just wow

$KURA accept the gift while you can

$KURA 💣💣💣

$KURA finally positive

$KURA keep it on your radar.. 🏦🏦

$KURA Let’s go!

$KURA Kura Oncology, Kyowa Kirin provide clinical data from KOMET-007 Kura Oncology and Kyowa Kirin provided positive updated clinical data from KOMET-007, a Phase 1a/1b trial of ziftomenib, a highly selective oral investigational menin inhibitor, in combination with standards of care in patients with newly diagnosed NPM1-mutan and KMT2A-rearrange acute myeloid leukemia. The data for the combination with cytarabine/daunorubicin (7+3) were presented as an oral presentation at the European Hematology Association 2025 Congress (EHA2025) being held in Milan, Italy from June 12-15, 2025. In the ongoing study, ziftomenib dosed once daily at 600 mg in combination with 7+3 continued to demonstrate robust and evolving clinical activity in patients with newly diagnosed AML. Among 71 response-evaluable patients, 92% achieved a composite complete remission and 80% achieved a complete remission at the time of data cutoff. A rate of CR minimal residual disease negativity of 71% for NPM1-m with a median time to MRD negativity of 4.7 weeks and a rate of CR-MRD negativity of 88% for KMT2A-r patients with a median time to MRD negativity of 4.4 weeks were observed. Ziftomenib did not delay time to neutrophil and platelet count recovery, which was comparable to intensive chemotherapy regimens.

$KURA someone actually asked Cramer about Kura yesterday lol

$KURA just waiting here with my thumb in my you know what...

$KURA what’s your target for tonight?👀.....👀

$KURA 👋👋👋

$KURA pick me up @ $6.73